In addition, our analysis was conducted on primary tumor samples collected in the pretrastuzumab era and without assessment of HER2 expression thus failing to account for the change in treatment landscape since the introduction of trastuzumab for treatment of HER2‐positive EBC. The gene discussed is ERBB2; the disease is neoplasm.